HHS IG: CMS Overspent By $251M On Infusion Drugs Over 18 Months

By John Wilkerson / April 22, 2015 at 3:58 PM
The HHS Office of Inspector General said CMS could have reduced Medicare spending on infusion drugs by $251 million over an 18-month period by adopting IG recommendations to use a different method for setting reimbursement for drugs used with implantable pumps. Those infusion drugs are covered under the durable medical equipment benefit because infusion therapy often is provided in the home, rather than in facilities. The IG recommendations do not apply to the reimbursement-setting methodology used for injected drugs administered...


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.